ERBB2 and breast carcinoma: Triple negative breast cancer (TNBC), which accounts for around 12–17% of all breast cancer cases, is a subtype that stands out as particularly aggressive and difficult to treat due to the absence of the classic therapeutic targets estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) [1,2].